Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.

dc.contributor.authorOrtíz, Raúl
dc.contributor.authorQuiñonero, Francisco
dc.contributor.authorGarcía-Pinel, Beatriz
dc.contributor.authorFuel, Marco
dc.contributor.authorMesas, Cristina
dc.contributor.authorCabeza, Laura
dc.contributor.authorMelguizo, Consolación
dc.contributor.authorPrados, Jose
dc.date.accessioned2025-01-07T16:56:43Z
dc.date.available2025-01-07T16:56:43Z
dc.date.issued2021-04-24
dc.description.abstractThe development of drug resistance is one of the main causes of cancer treatment failure. This phenomenon occurs very frequently in different types of cancer, including colon and pancreatic cancers. However, the underlying molecular mechanisms are not fully understood. In recent years, nanomedicine has improved the delivery and efficacy of drugs, and has decreased their side effects. In addition, it has allowed to design drugs capable of avoiding certain resistance mechanisms of tumors. In this article, we review the main resistance mechanisms in colon and pancreatic cancers, along with the most relevant strategies offered by nanodrugs to overcome this obstacle. These strategies include the inhibition of efflux pumps, the use of specific targets, the development of nanomedicines affecting the environment of cancer-specific tissues, the modulation of DNA repair mechanisms or RNA (miRNA), and specific approaches to damage cancer stem cells, among others. This review aims to illustrate how advanced nanoformulations, including polymeric conjugates, micelles, dendrimers, liposomes, metallic and carbon-based nanoparticles, are allowing to overcome one of the main limitations in the treatment of colon and pancreatic cancers. The future development of nanomedicine opens new horizons for cancer treatment.
dc.identifier.doi10.3390/cancers13092058
dc.identifier.issn2072-6694
dc.identifier.pmcPMC8123136
dc.identifier.pmid33923200
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8123136/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/13/9/2058/pdf?version=1619486583
dc.identifier.urihttps://hdl.handle.net/10668/28083
dc.issue.number9
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectPARP
dc.subjectcancer stem cells
dc.subjectcolon cancer
dc.subjectdrug resistance
dc.subjectmiRNA
dc.subjectnanomedicine
dc.subjectpancreatic cancer
dc.subjecttumor microenvironment
dc.titleNanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8123136.pdf
Size:
2.33 MB
Format:
Adobe Portable Document Format